Topic: Psoriasis

News | June 17, 2019

Lilly: Taltz Tops Adalimumab for PsA in Head-to-Head

Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a...

News | June 12, 2019

Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCD

Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli...

News | May 23, 2019

FDA Approves Sorilux for Adolescent Plaque Psoriasis

The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in...

Harnessing the Power of Humor for Psoriasis

Humor can create positive changes in our thoughts, feelings, behaviors, and biochemistry and can also influence how patients cope.

Paul Osincup, MA

Years ago, if someone had told me, as a professional comedian and humorist, that I would author an article in Practical Dermatology®, I would have made a strong wager against it. Back then, I was far too immature to be trusted with...

Read Article

News | April 25, 2019

FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasis

The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical...

VIDEO | July 29, 2019

Nanotechnology Advances

Meeting Coverage | 2019 AAD Summer Meeting

New York, NY: July 25 - 28, 2019

Adam Friedman, MD, FAAD

News | July 25, 2019

New AAD, NPF Guidelines Address Psoriasis Phototherapy

News | July 19, 2019

Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019

News | July 2019

Recent Developments

DermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25 thumbnail

Video | June 27, 2019

DermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25

DermWire TV

News | June 25, 2019

Duobrii Lotion for Plaque Psoriasis Hits Shelves

News | June 25, 2019

AbbVie to Acquire Allergan

News | June 21, 2019

L’Oréal Rewards Social Initiatives Led By Dermatologists at WCD

Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCD image

News | June 17, 2019

Lilly: Taltz Tops Adalimumab for PsA in Head-to-Head

News | June 17, 2019

Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Disease

DermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology thumbnail

Video | June 13, 2019

DermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology

DermWire TV

Digital Insert | June 2019 Insert

Treatment Considerations in the Short- and Long-Term Management of Plaque Psoriasis: Is There A Role for Tazarotene?

Tazarotene is almost a forgotten entity in management of psoriasis, despite quality data showing it can be both tolerable and effective—when used appropriately.